Zafgen Announces Positive Results From Phase 2 Clinical Trial of Beloranib in Hypothalamic Injury Associated Obesity

Foundation Medicine Launches ICE 2, Its New Version of Interactive Cancer Explorer, Featuring PatientMatch

bluebird bio to Present at the 33rd Annual J.P. Morgan Healthcare Conference

CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments

Foundation Medicine to Present at the J.P. Morgan Healthcare Conference

Global Blood Therapeutics Completes $48 Million Series B Financing

Jounce Therapeutics to Present at the J.P. Morgan Healthcare Conference

MyoKardia to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Agios Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12

CytomX Expands Leadership Team with Addition of Michael Kavanaugh, M.D., as Chief Scientific Officer and Head of Research and Early Development

Global Blood Therapeutics to Present at Upcoming Investor Conferences

SAGE Therapeutics to Present at 33rd Annual J.P. Morgan Healthcare Conference

SAGE Therapeutics Added to NASDAQ Biotechnology Index

Agios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

Zafgen Added to NASDAQ Biotechnology Index

Foundation Medicine to Be Added to NASDAQ Biotechnology Index

Zafgen Announces Initiation of Phase 2b Trial of Beloranib in Severe Obesity

Rhythm Appoints Fred T. Fiedorek, M.D., Chief Medical Officer

Voyager Therapeutics and MassBiologics Announce Strategic Collaboration for Viral Vector Manufacturing

Agios Pharmaceuticals Announces Pricing of $220 Million Public Offering of Common Stock

Agios Pharmaceuticals Announces Proposed Offering of Common Stock

Agios Pharmaceuticals Appoints Kaye Foster-Cheek to its Board of Directors

New Clinical Data Supports the Use of FoundationOne® Heme to Enable Informed Treatment Decisions in a Wide Range of Hematologic Malignancies

FoundationOne® Identifies Clinically Relevant Genomic Alterations in Patients with Advanced Breast Cancers

Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for Patients with Systemic Mastocytosis at 2014 American Society of Hematology Annual Meeting

Agios Announces Celgene Decision to Extend Discovery Phase of Global Strategic Collaboration to April 2016

bluebird bio Announces Data Demonstrating First Four Patients with β-Thalassemia Major Treated with LentiGlobin™ are Transfusion-Free

Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency

Treatment for Relapsed Multiple Myeloma Patients Guided by FoundationOne® Heme Results in Promising Clinical Activity

Global Blood Therapeutics’ GBT440 Demonstrates Ability to Positively Impact Fundamental Sickle Cell Disease (SCD) Processes in Studies Presented at 2014 American Society of Hematology (ASH) Conference

Ablexis Announces Availability of the AlivaMab Mouse Technology and Settlement of the Litigation with Regeneron Pharmaceuticals, Inc.

Allena Pharmaceuticals Secures $25 Million Series B Financing

NinePoint Medical Appoints Christopher von Jako, Ph.D., to Chief Executive Officer

Afferent Pharmaceuticals Announces the Election of Dr. Peter Hirth to the Company’s Board of Directors

Foundation Medicine Appoints David J. Daly as Chief Commercial Officer

Foundation Medicine and Flatiron Health Collaborate to Develop First-in-Class Data Platform to Accelerate Precision Medicine for Cancer

Global Blood Therapeutics to Present New Data Highlighting Therapeutic Potential of GBT440 in Sickle Cell Disease (SCD) at 2014 American Society of Hematology (ASH) Conference

Nurix Launches Collaboration with Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute to Expand its Drug Discovery Program

Editas Medicine Licenses Genome Editing Technology from Broad Institute and Harvard University

Editas Medicine Licenses Genome Editing Technology from Massachusetts General Hospital

Eleven Biotherapeutics to Present at Oppenheimer 25th Annual Healthcare Conference

Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published in The Lancet

Eleven Biotherapeutics Announces Additional Financing of $20 Million

Foundation Medicine to Present at the Piper Jaffray Healthcare Conference

Blueprint Medicines Unveils New Drug Discovery Program for Patients with RET Fusions at 26th EORTC-NCI-AACR Symposium

Foundation Medicine\'s Novel Companion Diagnostic Test, Developed in Collaboration with Clovis Oncology, Identifies Expanded Subgroup of Cancer Patients with the Potential to Respond to Clovis Oncology\'s PARP inhibitor, Rucaparib

Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)

Blueprint Medicines to Present Discovery of New Cancer Drug Targets at EORTC-NCI-AACR Symposium

Eleven Biotherapeutics Reports Third Quarter 2014 Financial Results

bluebird bio Reports Fiscal Third Quarter 2014 Financial Results